EMBO Molecular Medicine

metrics 2024

Fostering Global Collaboration in Molecular Medicine

Introduction

EMBO Molecular Medicine, published by WILEY, stands as a premier forum within the field of molecular medicine, advancing scholarly dialogue and research since its launch in 2009. With an impressive impact factor reflected in its Q1 categorization and ranking as the 12th journal in the discipline of Molecular Medicine by Scopus, it serves as a vital resource for researchers, professionals, and students alike. Operating under an Open Access model, EMBO Molecular Medicine ensures that cutting-edge research is freely accessible, fostering greater collaboration and innovation among the global scientific community. Located in the United Kingdom, the journal encompasses a broad scope, featuring high-quality studies that bridge the gaps between basic molecular biology and clinical applications, making significant impacts on health and disease. With a commitment to excellence and a continuously evolving repertoire of research, this journal play a crucial role in shaping the future of biomedical research and therapy.

Metrics 2024

SCIMAGO Journal Rank3.96
Journal Impact Factor9.00
Journal Impact Factor (5 years)11.00
H-Index142
Journal IF Without Self9.00
Eigen Factor0.02
Normal Eigen Factor3.60
Influence3.75
Immediacy Index1.60
Cited Half Life6.20
Citing Half Life7.50
JCI2.19
Total Documents1735
WOS Total Citations12283
SCIMAGO Total Citations37902
SCIMAGO SELF Citations269
Scopus Journal Rank3.96
Cites / Document (2 Years)8.20
Cites / Document (3 Years)8.73
Cites / Document (4 Years)9.00

Metrics History

Rank 2024

Scopus

Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #12/178
Percentile 93.26
Quartile Q1

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 15/189
Percentile 92.30
Quartile Q1

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 11/189
Percentile 94.18
Quartile Q1

Quartile History

Similar Journals

Molecular Oncology

Connecting the Dots in Cancer Biology and Treatment.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

EXPERT OPINION ON THERAPEUTIC TARGETS

Unveiling the mechanisms that drive therapeutic breakthroughs.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Molecular Biomedicine

Innovating Solutions through Molecular Insights
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

npj Regenerative Medicine

Advancing the Frontiers of Regenerative Medicine.
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Regenerative Medicine, published by NATURE PORTFOLIO, is at the forefront of research and innovation in the field of regenerative medicine, fostering a deep understanding of cellular and molecular processes that can be leveraged for therapeutic advancements. Launched as an Open Access journal since 2016, it ensures wide dissemination of knowledge, allowing researchers, professionals, and students to access high-quality articles without barriers. With an impressive impact, it holds Q1 ratings across multiple categories including Biomedical Engineering, Cell Biology, Developmental Biology, and Medicine (miscellaneous) as of 2023, indicating its critical role in shaping contemporary scientific discourse. The journal ranks notably within the top 10% in multiple Scopus categories, indicating its commitment to publishing pioneering research that addresses pressing challenges in regenerative therapies. Addressing the dynamic convergence of disciplines, npj Regenerative Medicine is poised to not only impact academic thought but also translate into clinical applications, making it a pivotal resource for those invested in the future of medicine.

Biomolecules & Therapeutics

Connecting Researchers to Shape the Future of Medicine
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

CURRENT MOLECULAR MEDICINE

Pioneering Interdisciplinary Research in Molecular Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5240Frequency: 10 issues/year

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Advancing Insights into Molecular Mechanisms
Publisher: ELSEVIERISSN: 0925-4439Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Empowering Researchers with Open Access Knowledge
Publisher: WILEYISSN: 1582-1838Frequency: 12 issues/year

Journal of Cellular and Molecular Medicine, published by Wiley, stands at the forefront of research excellence in the fields of cell biology and molecular medicine. With an impressive impact factor reflected in its 2023 Q2 category ranking for both Cell Biology and Molecular Medicine, this journal provides a vital platform for researchers and professionals alike, fostering innovative findings and groundbreaking discoveries since its inception in 2000. Maintaining an open access policy since 2012, the journal ensures that knowledge is freely disseminated, promoting collaboration and progress across the scientific community. With robust rankings in the Scopus database, including a position within the top 85th percentile in Molecular Medicine, the journal remains committed to advancing understanding of cellular functions and their implications in health and disease. Researchers, professionals, and students will find a treasure of high-quality articles and reviews that not only catalyze academic dialogue but also contribute significantly to practical applications in the life sciences.

Disease Models & Mechanisms

Innovating Solutions Through Disease Mechanisms
Publisher: COMPANY BIOLOGISTS LTDISSN: 1754-8403Frequency: 12 issues/year

Disease Models & Mechanisms is a distinguished peer-reviewed journal dedicated to elucidating the complex interplay of biological processes involved in disease through innovative modeling and mechanistic insight. Published by COMPANY BIOLOGISTS LTD in the United Kingdom, this Open Access journal has been committed to disseminating critical research since 2011, ensuring that valuable findings are accessible to a global audience. With an impressive impact factor and ranked in the Q1 category in fields such as Biochemistry, Genetics, and Molecular Biology, Immunology, Microbiology, Medicine, and Neuroscience, it stands out for its high-quality publications that significantly contribute to the scientific community. The journal encourages submissions that explore the latest breakthroughs in disease modeling and mechanisms, fostering a collaborative environment among researchers, professionals, and students alike. Readers can benefit from state-of-the-art studies covering a spectrum of diseases, providing insights that pave the way for innovative therapeutic strategies.

BIOMEDICAL RESEARCH-TOKYO

Exploring Pioneering Research in Biochemistry and Genetics
Publisher: BIOMEDICAL RESEARCH PRESS LTDISSN: 0388-6107Frequency: 6 issues/year

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.